Bright Minds Net Worth
Bright Minds Net Worth Breakdown | DRUG |
Bright Minds Net Worth Analysis
Bright Minds' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bright Minds' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bright Minds' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bright Minds' net worth analysis. One common approach is to calculate Bright Minds' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bright Minds' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bright Minds' net worth. This approach calculates the present value of Bright Minds' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bright Minds' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bright Minds' net worth. This involves comparing Bright Minds' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bright Minds' net worth relative to its peers.
Enterprise Value |
|
To determine if Bright Minds is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bright Minds' net worth research are outlined below:
| Bright Minds is way too risky over 90 days horizon | |
| Bright Minds appears to be risky and price may revert if volatility continues | |
| Bright Minds has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.37 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bright Minds Biosciences currently holds about 8.64 M in cash with (7.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.71. | |
| Bright Minds has a frail financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting |
Bright Minds uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bright Minds Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bright Minds' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Bright Minds' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bright Minds is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bright Minds Biosciences backward and forwards among themselves. Bright Minds' institutional investor refers to the entity that pools money to purchase Bright Minds' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisorshares Investments, Llc | 2024-06-30 | 181 K | Jane Street Group Llc | 2024-06-30 | 10.9 K | Royal Bank Of Canada | 2024-06-30 | 510 | Aspire Private Capital, Llc | 2024-09-30 | 100.0 | Blackrock Inc | 2024-06-30 | 1.0 |
Follow Bright Minds' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 225.49 M.Market Cap |
|
Project Bright Minds' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.23) | (1.29) | |
| Return On Capital Employed | (1.28) | (1.35) | |
| Return On Assets | (1.23) | (1.29) | |
| Return On Equity | (1.28) | (1.35) |
When accessing Bright Minds' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bright Minds' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bright Minds' profitability and make more informed investment decisions.
Evaluate Bright Minds' management efficiency
Bright Minds Biosciences has return on total asset (ROA) of (0.2886) % which means that it has lost $0.2886 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.518) %, meaning that it created substantial loss on money invested by shareholders. Bright Minds' management efficiency ratios could be used to measure how well Bright Minds manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.29. The current Return On Capital Employed is estimated to decrease to -1.35. At this time, Bright Minds' Intangible Assets are most likely to increase significantly in the upcoming years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.60 | 2.80 | |
| Tangible Book Value Per Share | 1.60 | 2.80 | |
| Enterprise Value Over EBITDA | (0.16) | (0.17) | |
| Price Book Value Ratio | 1.39 | 1.32 | |
| Enterprise Value Multiple | (0.16) | (0.17) | |
| Price Fair Value | 1.39 | 1.32 | |
| Enterprise Value | 10.9 M | 10.4 M |
Bright Minds Biosciences benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Return On Equity (0.52) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bright Minds insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bright Minds' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bright Minds insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cormorant Asset Management, Lp over two weeks ago Acquisition by Cormorant Asset Management, Lp of 184331 shares of Bright Minds at 21.7 subject to Rule 16b-3 | ||
Cormorant Asset Management, Lp over a month ago Insider Trading |
Bright Minds Corporate Filings
6K | 21st of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 19th of November 2024 Other Reports | ViewVerify | |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 6th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Bright Minds Earnings per Share Projection vs Actual
Bright Minds Corporate Management
| FCCP MD | Chief Officer | Profile | |
| Jan MSc | Interim Director | Profile | |
| Emer MBA | Consultant | Profile | |
| Gideon Shapiro | VP Discovery | Profile | |
| Ian McDonald | CEO, CoFounder | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.